Answers are grounded in this paper and cite their sources.
BACKGROUND: Cytokines and inflammatory mediators are the hallmarks of sepsis. Extracorporeal cytokine hemoadsorption devices are the newer clinical support system to overcome the cytokine storm during sepsis. AIM: To retrospectively evaluate the clinical outcomes of patients admitted in intensive care unit with septic shock with different etiologies. METHODS: The laboratory parameters including biomarkers such as procalcitonin, serum lactate and C-reactive protein; and the hemodynamic parameters; mean arterial pressure, vasopressor doses, sepsis scores, cytokine levels and other vital parameters were evaluated. We evaluated these outcomes among survivors and non-survivors. RESULTS: therapy less than 48 h after onset of septic shock survived and the maximum duration of stay for 70% of these patients in intensive care unit was less than 15 d. CONCLUSION: is a safe and well tolerated rescue therapy option in patients with septic shock. However, early (preferably within < 48 h after onset of septic shock) initiation could result in better clinical outcomes. Further randomized trials are needed to define the potential benefits of this new treatment modality.
No takes yet. Share an insight, caveat, or question.
Mehta et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: